Diabetic Ketoacidosis


Diabetic ketoacidosis (DKA) is one of the most serious life-threatening emergencies in diabetic patients. DKA can cause morphological and functional neurological changes. Cerebral edema is the most severe central nervous system complication associated with DKA. The clinical picture of cerebral edema includes altered mentation, fluctuating level of consciousness, decorticate or decerebrate posturing, cranial nerve palsy, and abnormal neurogenic respiratory pattern. A more frequent subclinical form of cerebral edema may continue in DKA patients leading to a late-onset cognitive impairment.

Experimental studies have shown that PMZ-2123 prevents the development of neurological complications in diabetic ketoacidosis.

Intravenous administration of PMZ-2123 prevents the development of cerebral edema in an animal model with diabetic ketoacidosis.

PMZ-2123 is in preclinical stage of development.


Status of Diabetic Ketoacidosis

Product Pre-Clinical Clinical Market
Phase 1 Phase 2 Phase 3
Diabetic Ketoacidosis (PMZ-2123)